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Should we mind for late neurologic manifestations from novel coronavirus?
We read with great interest the article published by Montalvan et al.
[1] reviewing the neurological manifestations of COVID-19 and other
coronavirus infections. The review was focused on the acute compli-
cations described in humans and in animal models of coronavirus in-
fection. So far, no cases of chronic neurological illness or late onset
neurological disease associated with the novel coronavirus (2019-
nCoV), the cause of Coronavirus disease 2019 (COVID-19), have been
published. However, from murine models it is known that even in
asymptomatics, the coronavirus may persist chronically in anterior
spinal cord causing late onset neurological disease manifesting as limb
paresis [2]. Genetic factors and host’s antiviral response may account
for late onset neurological disease development [3]. Importantly, even
in the absence of detectable active replication, murine Coronavirus can
mutate and persist chronically in the central nervous system causing
chronic demyelination [4].
These findings from animal models are relevant for different rea-
sons. Contrary to previous Coronavirus outbreaks that were limited to
Asian countries, the genetic pool of infected humans is diverse and
worldwide representative. In addition, genetic diversity and rapid
evolution is a recognizable feature of 2019-nCoV [5]. Hence, the pos-
sibility of late neurological disease associated with 2019-nCoV infection
as a result of the multiplicity of viral/host genetic-immune interactions
should be considered.
Considering that the majority of 2019-nCoV infections are asymp-
tomatic, and the fact that murine asymptomatics develop late neuro-
logical disease, theoretical or speculative anticipation of human in-
crease of late neurological diseases is reasonable. Continuing
surveillance and awareness of the possibility of late neurological com-
plications even in patients without precedent diagnosis of 2019-nCoV
infection is warrant.
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